Compare PRCH & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCH | ZURA |
|---|---|---|
| Founded | 2012 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 252.9M |
| IPO Year | N/A | N/A |
| Metric | PRCH | ZURA |
|---|---|---|
| Price | $8.95 | $4.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $17.56 | $11.38 |
| AVG Volume (30 Days) | ★ 1.4M | 434.3K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $442,483,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.06 | N/A |
| P/E Ratio | $33.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.72 | $0.97 |
| 52 Week High | $19.44 | $4.68 |
| Indicator | PRCH | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 67.07 |
| Support Level | $8.85 | $4.00 |
| Resistance Level | $9.28 | $4.58 |
| Average True Range (ATR) | 0.50 | 0.24 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 6.13 | 90.45 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has two reportable segments: The vertical Software segment provides software and services to home services companies. The Vertical Software segment software and services provide inspection, mortgage, and title companies on a subscription and transactional basis, several key businesses, including inspection software and services, title insurance software, mortgage software, moving services, mover and homeowner marketing, and measurement software for roofers. The insurance segment provides consumers with insurance and warranty products to protect their homes, earning revenue through premiums collected on policies, policy fees, and commissions. Majority revenue is from Insurance segment.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.